Amgen inks drug development deal worth up to $1.9B
Thousand Oaks-based Amgen has reached an agreement with Generate Biomedicines, a Massachusetts-based therapeutics company, to research, discover and create protein therapeutics, the company announced Jan. 6. According to the agreement, Amgen, one of the largest biotech companies in the world, will pay $50 million up front to fund the initial five programs, with a potential Read More →
Capsida’s new CEO hopes success is in the genes
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Our View: Deja vu as 2022 begins, but with some big differences
We begin 2022 as we ended 2021, with the newest variant of the virus dominating the headlines. As the Business Times goes to press on its first edition of the year, it is back to the future, as most meetings and live events have moved to virtual. Virtual meetings are a poor substitute for in-person, Read More →
2021: The Year In Review
The Dec. 31 print edition of the Pacific Coast Business Times marks our annual Year In Review, featuring the biggest and best stories we published in 2021. Here is a look through our archives at the past year, a year marked by big deals, economic recovery and public health victories, but also by recurring waves Read More →
Hardy prepares to sell swab-free COVID-19 test developed at Cal Poly
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen’s new asthma treatment gets FDA approval
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Omicron complicates some office reopenings
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
